PT  - JOURNAL ARTICLE
AU  - Schechter, Naomi R.
AU  - Wendt, Richard E.
AU  - Yang, David J.
AU  - Azhdarinia, Ali
AU  - Erwin, William D.
AU  - Stachowiak, Anne M.
AU  - Broemeling, Lyle D.
AU  - Kim, E. Edmund
AU  - Cox, James D.
AU  - Podoloff, Donald A.
AU  - Ang, K. Kian
TI  - Radiation Dosimetry of <sup>99m</sup>Tc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck
DP  - 2004 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1683--1687
VI  - 45
IP  - 10
4099  - http://jnm.snmjournals.org/content/45/10/1683.short
4100  - http://jnm.snmjournals.org/content/45/10/1683.full
SO  - J Nucl Med2004 Oct 01; 45
AB  - This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging. Methods: Whole-body scanning was performed on 6 patients with head and neck squamous cell carcinoma up to 24 h after administration of 99mTc-EC-C225. Alternate patients who had been randomized to receive C225 in a phase III trial received 99mTc-EC-C225 before their 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6, respectively). Radiation dosimetry was assessed using the MIRD method. Results: The critical organ was the kidney, with an average radiation-absorbed dose for all 6 patients of 0.0274 mGy/MBq. The average total-body absorbed dose was 0.0022 mGy/MBq (0.243 cGy/1,110 MBq). Conclusion: The new radiopharmaceutical 99mTc-EC-C225 appears to have reasonable dosimetric properties for a diagnostic nuclear medicine agent. Correlation of the imaging results with clinical findings is the next step.